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Abstract
Background: Lifestyle modifications, especially dietary interventions, assume an increasingly more important
role in the population-based approach to cardiovascular diseases risk reduction. Buckwheat is a highly nutritional
food component that has been shown to provide a wide range of beneficial effects. 
Objective: The aim of the study was to examine whether a replacement diet with buckwheat products could
provide additive protective effects in reducing cardiovascular risk factors, including blood glucose, insulin, lipids,
oxidative damage and pro-inflammatory markers, in comparison to a similar replacement diet using products made
from organic wheat.
Methods: Twenty-one participants at high risk for cardiovascular disease (11 F; 10 M; mean age 51.3 ± 13.4)
were randomized to receive products (bread, pasta, biscuits and crackers), made from either buckwheat-enriched
semi-wholegrain wheat or control semi-wholegrain wheat for 8 weeks in a single-blinded crossover trial. A washout
period of 8 weeks was implemented between the two intervention phases, in which participants were permitted to
eat all foods according to their normal eating habits. Blood analyses were performed at the start and end of each
intervention period, respectively.
Results: Consumption of buckwheat products resulted in a significant amelioration in total cholesterol (-4.7%),
low-density lipoprotein cholesterol (-8.5%), triglycerides (-15%), glucose (-5.8%) and insulin (-17%) from baseline
levels, independently of age, sex, body mass index and hypertension. Moreover, thiobarbituriic acid reactive
substances (TBARs) levels were significantly reduced by 29.5%. A concomitant significant increase in plasma
ORAC levels (+9.7%) was observed. No significant differences from baseline in the same participants were
observed after consumption of the control products.
Conclusion: Our results suggest that a replacement diet with buckwheat products exert a protective effect on the
development of cardiovascular disease by reducing circulating cardiovascular risk factors and markers of oxidative
stress.
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Introduction
Worldwide morbidity and mortality from infectious diseases is
being replaced by chronic diseases, commonly referred to as non-
communicable diseases, of which cardiovascular diseases (CVD)
account for the majority of existing deaths. [1-3] Diet and nutrition are
important factors in the promotion and maintenance of good health,
and an unhealthy diet represents a modifiable, behavioural risk factor
that impacts on the global risk profile, resulting in the progression of
chronicdisease. [3] Hence, nutritional research has shifted from
focusing predominantly on alleviating nutrient deficiencies to include
chronic disease prevention [1].
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Cereals and pseudo cereals represent an excellent source of dietary
energy for humans, and in most countries and regions, form the major
dietary component. Common buckwheat (Fagopyrum esculentum), a
gluten-free pseudo cereal, which, besides being recognized as a
nutritionally valuable source of protein, lipid, dietary fibre and
minerals, is receiving increased attention as a potential functional food
[4,5]. The cardiovascular, anti-cancer and anti-diabetic health benefits
attributed to buckwheat have been associated with improved
antioxidant, hypocholesterolemic and hypoglycemic effects, as
reported from studies conducted predominantly on animal models and
in vitro experiments. [4,5].
To date, relatively few studies have been conducted on humans. [5]
It is noteworthy that in a large trial conducted by Zhang et al. [6], life-
long consumption of buckwheat as a staple food was associated with
lower hypertension, dyslipidaemia, and hyperglycaemia. Of interest,
besides the low number of studies conducted on humans, an
insufficient number of studies have been performed on the anti-
inflammatory activity of buckwheat, thereby making it difficult to draw
conclusions on these parameters.
The objective of the present work was to investigate whether
buckwheat consumption in a healthy Italian population, but with a
high risk for cardiovascular problems, was specifically associated with
improvements in CVD risk profile by examining lipid, glucose and
oxidative parameters, as well as inflammatory parameters.
Materials and Methods
Study population
Twenty-one individuals (11 women and 10 men) were recruited
from the Unit of Clinical Nutrition of the Department of Experimental
and Clinical Medicine, University of Florence, Careggi University
Hospital. Participants were eligible if they were older than 18 years and
fulfilled >1 of the following criteria: being overweight (Body Mass
Index >25.1 kg/m2) and by the concomitant presence of at least one the
following criteria:
• Circulating levels of total cholesterol >190 mg/dL, not on drug
treatment (measured no more than 3 months prior to the start of
the study).
• Circulating levels of LDL cholesterol >115 mg/dL, not on drug
treatment (measured no more than 3 months prior to the start of
the study).
• Circulating levels of triglycerides >150 mg/dL, not on drug
treatment (measured no more than 3 months prior to the start of
the study).
• Circulating levels of fasting blood glucose >110 mg/dL but <126
mg/dL, not on drug treatment (measured no more than 3 months
prior to the start of the study).
Criteria for exclusion included a history of serious medical
conditions including diabetes, liver diseases, renal diseases and cancer,
the adherence to a specific diet or other medically prescribed diets,
gluten and buckwheat allergies, gastrointestinal disorders (e.g.
inflammatory bowel disease, irritable bowel syndrome or other chronic
gastrointestinal complaints), alcohol or drug abuse, pregnancy,
lactation and an unstable medical status. Individuals with a recent
episode of myocardial infarction, stroke, or any other severe pathology,
considered to pose a risk to the individual or to confound the results of
the study, were all excluded. After explaining the protocol to the
participants and obtaining written informed consent, a precise medical
history was obtained from each individual.
Experimental and control wheat
The common buckwheat (Fagopyrum esculentum Moench.) variety
Lileja, utilized as the experimental grain in the present project. The
latter was cultivated in the Italian province of Umbria and obtained
through the project entitled “Saraceno-Umbria” Act 1.2.4 PSR under
Umbrian Regional law. Cultivation was under organic conditions, in
that no fertilizers or pesticides were used. The dehulled seeds (raw
groats) were stone-milled at the Molino Marini (Foligno, Perugia).
Since different countries utilize different terminology to classify the
different types of milled flour, we report the ash content (positively
correlated to the extraction rate) for comparative purposes. The
experimental buckwheat had an ash content of 1.35%-1.49%, and was
considered “wholegrain”. As the control (from here on referred to as
the control wheat), a mix of organic commercial Italian durum
(Triticum durum Desf.) varieties and soft wheat (Triticum aestivum L.)
varieties, respectively, were used. Semi-wholegrain granulated
semolina (ash content 1.0%-1.35%) and semi-wholegrain flour (ash
content, 0.95%), respectively, were processed by Molino SIMA.
For the buckwheat-enriched pasta, 50% wholegrain buckwheat flour
was blended with 50% semi-wholegrain granulated semolina. Pastificio
Artigiano FABBRI s.a.s. (Strada in Chianti, Firenze, Italy) prepared the
pasta (with no additives) from both the buckwheat-enriched and
control semolina, according to the artisan manufacturing procedures.
For baking purposes, 40% wholegrain buckwheat flour was mixed with
the semi-wholegrain flour. Panificio Menchetti Pietro di Santi e Figli
s.n.c. (Cesa Marciano della Chiana, Arezzo, Italy), an artisan enterprise
was responsible for the preparation of the bread, biscuits and crackers
using both the buckwheat-enriched and control flour. Naturally,
leavened Tuscan-style sourdough bread was prepared. Besides the flour
composition, dry crackers contained 20% extra-virgin olive oil. The
biscuits were prepared using 10% sugar, 5% butter, and one egg per
100 g flour.
Study protocol
The study was a randomized, single blinded, cross-over trial to test
the effect of a replacement diet with buckwheat products on markers
related to cardio-metabolic risk. The experimental products were
compared with a similar replacement diet using organic semi-whole
grain products. The participants were randomly assigned, using a
computerized random number generator, to one of two treatment
orders starting with buckwheat products or control products,
respectively. Each dietary phase lasted 8 weeks with an 8 week wash-
out period. After the wash-out period, participants were crossed over
to the opposite treatment.
The enrolled subjects were examined four times during the study,
one before and one after each intervention period. During each clinical
visit, fasting body weight was recorded and BMI was calculated as
weight (kg)/height (m)2. Peripheral venous blood was drawn between
07:00-09:30 h after a 12 h fasting period. One day before each
examination, subjects were asked to refrain from engaging in any
strenuous exercises. Furthermore, the participants were asked not to
alter their physical activity habits during the study. A baseline
questionnaire indicated that 14% of the subjects had physical activity
levels equivalent to 30-60 min/d and 86% reported to have a sedentary
lifestyle.
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The buckwheat or control products provided for the 8 week
intervention periods were as follows: 500 g per week of pasta, 1 kg per
week of bread, 500 g per month of crackers and 1 kg per month of
biscuits. During the intervention phases, all participants were not
permitted to eat other grains products, whereas when on the wash-out
period, they were encouraged to eat “as usual”. To ensure consumption
of the products provided and the maintenance of usual lifestyle habits,
the researcher interacted with the participants on a weekly basis.
The present study was conducted according to the guidelines,
prescribed by the Declaration of Helsinki, and the local ethic
committee approved the protocol. Written informed consent was
obtained from all the subjects. Recruitment began in September 2014,
and the experimental trials took place between January 2015 and June
2015.
Physiological parameters of the buckwheat and control
Total polyphenol content, total anti-radical power (ARP, using the
DPPH method) and the mineral element content were measured as
previously described [7].
Blood measurements
After an overnight fasting for 10-12 h, a venous blood sample was
obtained from each subject. Serum was separated after centrifuging at
3000×g for 15 min at 4°C. Samples were stored in aliquots at -80 °C
until analysis. Lipid variables, blood glucose and serum electrolytes
were assessed by conventional methods. Pro- and anti-inflammatory
cytokines were determined by using the Bio-Plex cytokine assay (Bio-
Rad Laboratories Inc., Hercules, CA, USA), according to
manufacturer’s instructions.
Assessment of ROS production and total antioxidant
capacity
The measurement of leukocyte (lymphocyte, monocyte and
granulocyte) ROS generation was performed as described previously
[7,8]. Similarly, the thiobarbituric acid reactive substance (TBARS)
assay kit (Oxitek-ZeptoMetrix Corporation Buffalo, NY, USA) was
used to measure fatty acid peroxidation. Total Antioxidant Capacity
(TAC), accounting for total hydrophilic ROS scavengers, was measured
using the ORAC assay (Oxygen Radical Absorbance Capacity). The
determination was based on the inhibition of the peroxyl-radical-
induced oxidation initiated by thermal decomposition of azo-
compounds, such as 2,2-azobis(2-amidinopropane) dihydrochloride
(AAPH), as reported previously [8].
Statistical analysis
The SPSS software version 20 was used to statistically analyse all
data. Results were expressed as means with standard deviations for
normally distributed variables, and as medians and ranges for non-
normally distributed data. The differences between the groups were
tested by using the Mann-Whitney U test. The two interventions were
analysed by taking into account both periods, in the two groups of
subjects, at different stages. Comparisons between the mean
differences of variables in the two groups (buckwheat and control)
were performed using paired t-test. A general linear model for
repeated measurements, adjusted for age, gender, BMI, smoking habits,
hypertension, dyslipidaemia and familial history for cardiovascular
disease, was performed to compare the effect of the two treatments.
One-way analysis of variance was used for testing differences between
(1) buckwheat and control flour and semolina samples, respectively;
(2) changes in experimental and control groups. The absolute change
for each variable tested (mean value at baseline subtracted from the
mean value after intervention for each subject) was estimated with
independent t sample tests. A P value of ≤ 0.05 was considered
significant for all the analyses.
Results
Characteristics of the study population
Twenty-one subjects, with a median age of 56 years (range: 28-69)
and a mean ± SD BMI of 26.4 ± 4.3 were enrolled in the study (Table
1).
Characteristic Total (n=21)
Age, median (range) 56 (28-69)
Sex, (M/F) 11/10
BMI, mean ± SD 26.4 ± 4.3
Hypertension, n (%) 3 (14%)
Dyslipidemia, n (%) 8 (38%)
Current smokers, n (%) 3 (14%)
Familiarity for CAD 1 (5%)
Table 1: Baseline characteristics of the study population. BMI=Body
Mass Index; SD=Standard Deviation; CAD=Coronary Artery Disease.
Three participants were smokers during the trial, 3 were
hypertensive (under an optimal therapeutic control) and 8 were
dyslipidemic. At baseline, no significant differences were found
between the experimental and control groups for any demographic or
clinical measures (data not shown). Moreover, at the end of the
intervention programme, BMI did not change significantly with
respect to baseline.
Physiological parameters of the buckwheat and control
Total polyphenol content, and particularly ARP, was significantly
higher in the buckwheat-enriched semolina and flour than in the
respective control semolina and flour (Table 2). Moreover, Ca2+, Fe2+,
K+, M+, Na+ and P+ were significantly higher in both the buckwheat-
enriched semolina and flour in comparison to the controls (Table 2).
Variable Buckwheat semolina Control semolina p value Buckwheat flour Control flour p value
Total protein, % 12 ± 0.4 14.3 ± 0.4 0.002 9.9 ± 0.4 10.3 ± 0.08 0.165
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Calcium, mg/kg 839.9 ± 34 346.7 ± 7.3 <0.001 788.4 ± 21.2 354.8 ± 5.7 <0.001
Copper, mg/kg 6.6 ± 0.6 5.6 ± 0.7 0.133 5.3 ± 0.4 4.3 ± 0.1 0.014
Iron, mg/kg 48.1 ± 7.2 31 ± 4 0.023 41.2 ± 5.2 22.8 ± 0.5 0.004
Potassium, mg/kg 3037.8 ± 276.4 1969.8 ± 10.2 0.003 2716.4 ± 50.4 1531.6 ± 17.1 <0.001
Magnesium, mg/kg 2002.3 ± 161.9 789.7 ± 115.3 <0.001 1743.9 ± 240.1 673.1 ± 109.2 0.002
Manganese, mg/kg 9 ± 0.2 11.1 ± 0.4 0.001 10.2 ± 1.3 15.5 ± 1.3 0.008
Sodium, mg/kg 46.5 ± 2.6 11.3 ± 2.2 <0.001 52.7 ± 3.2 22.9 ± 2.2 <0.001
Phosphorus, mg/kg 3329.7 ± 374.2 2432 ± 112.8 0.016 3035.9 ± 202.4 1613.3 ± 41.3 <0.001
Zinc, mg/kg 22.9 ± 3.3 25.3 ± 0.2 0.277 20.2 ± 1.3 18.3 ± 0.5 0.077
Total polyphenols, mg/g DM 4.6 ± 0.2 1.8 ± 0.08 <0.001 3.8 ± 0.2 1.5 ± 0.02 <0.001
ARP (antiradical power) 30.7 ± 2.7 5.9 ± 0.7 <0.001 25.1 ± 2.1 4.8 ± 0.2 <0.001
Table 2: Composition of buckwheat and control wheat (for 100 g). Data are reported as mean and standard deviation. One-way ANOVA test.
Biochemical variables
In order to analyse the changes in the circulatory biochemical
variables after the interventions, a general linear model adjusted for
age, gender, BMI, smoking habits, hypertension, dyslipidaemia and
familial history for cardiovascular disease was performed. Adjusted
values for biochemical and oxidative stress-related risk factors, before
and after the dietary interventions in both groups, were reported in
Table 3.
Variables
Buckwheat p † Control
p †
p for
change †
pre post change pre post change
Lipid profile
Total cholesterol,
mg/dL 202.2 ± 43 192.8 ± 43.8 *
-9.4
(-19.9;
-3.9)
0 199.2 ± 47.6 202 ± 39.2 2.9 (-8.9;14.6)° 0.59 0.028
LDL-cholesterol,
mg/dL 121.3 ± 41.2 111.1 ± 33.1 *
-10.4
(-18.2;
-2.5)
0.01 115.5 ± 38.9 118.8 ± 36.8 3.3 (-3.0;9.5)° 0.27 0.016
HDL-cholesterol,
mg/dL 62.6 ± 23.1 59.5 ± 22.4 *
-3.7 (-6.13
-1.1) 0.01 60.2 ± 23.4 60.2 ± 23.4
0.05 (-2.4;
2.3) 0.96 0.068
Triglycerides,
mg/dL 112.8 ± 57.7 95.9 ± 41.5
-17.0
(-32.6;
-1.3)
0.03 113.7 ± 72.5 111.6 ± 50.4
-2.1
(-15.9;
11.8)
0.77 0.139
Glucometabolic profile
Blood glucose,
mg/dL 87.2 ± 8.6 82.2 ± 8.1 *
-5.1 (-8.4;
-1.7) 0.01 87.0 ± 9.0 85.0 ± 8.7
-1.9 (-4.0;
0.1) 0.06 0.135
Insulin, U/L 10 ± 5.4 8.3 ± 4.4 * -1.7 (-3.5;0.2) 0.06 9.4 ± 4.9 9.9 ± 5.7
-0.49
(-0.57;
1.54)°
0.35 0.045
HOMA - Index 2.2 ± 1.3 1.7 ± 1.0 * -0.5 (-0.9;-0.03) 0.04 2.1 ± 1.2 2.1 ± 1.3
0.04
(-0.22;
0.29)°
0.77 0.049
Mineral profile
Potassium, mEq/L 4.2 ± 0.3 4.1 ± 0.3 -0.1 (-0.3;0.03) 0.1 4.3 ± 0.3 4.0 ± 0.3 *
-0.3 (-0.4;
-0.2) 0 0.048
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Calcium, mEq/L 8.9 ± 0.3 8.9 ± 0.3
-0.07
(-0.2;
-0.09)
0.4 8.9 ± 0.4 9.0 ± 0.3
0.09
(-0.04;
0.2)
0.14 0.102
Magnesium,
mg/dL 2.0 ± 0.1 2.0 ± 0.1
0.04
(-0.02;
0.1)
0.15 2.0 ± 0.1 2.0 ± 0.2
0.04
(-0.03;
0.1)
0.23 1
Iron, mg/dL 84.6 ± 21.4 76.3 ± 25.1
-8.4
(-20.0;
3.3)
0.14 89.3 ± 27.8 77.8 ± 24.0
-11.5
(-32.1;
9.0)
0.23 0.792
Sodium, 138.8 ± 2.0 139 ± 1.6 0.15 (-0.9;1.2) 0.77 139.4 ± 2.2 139.6 ± 1.8
0.2 (-0.7;
1.1) 0.64 0.944
Oxidative stress profile
MDA, pg/mL 49.9 ± 30.5 35.2 ± 20.9 *
-14.7
(-23.5;
-6.0)
0 40.0 ± 42.9 38.0 ± 33.7
-2.0
(-21.8;
17.9)°
0.83 0.276
ROS-
Lymphocytes 644 ± 277.4 551.1 ± 258
-92.2
(-193.6;
7.9)
0.06 531.7 ± 179.5 643.5 ± 133.2 *
111.8
(13.1;
210.5)°
0.03 0.015
ROS-Monocytes 1163 ± 444.4 1244.2 ± 380.6
81.2
(-147.5;
309.9)
0.44 1045.5 ± 358.4 1253.3 ± 296.9 * 207.9 (8.5;407.2) 0.04 0.361
ROS-
Granulocytes 1642.5 ± 656.6 1762.2 ± 566.8
119.7
(-165.8;
405.2)
0.36 1380.6 ±  ± 433.6 1684.1 ± 378.2 *
303.5
(12.6;
594.4)
0.04 0.376
TAC 18.5 ± 2.7 20.3 ± 2.9 * 1.76 (0.39;3.12) 0.02 19.1 ± 2.4 19.3 ± 2.2
0.25
(-0.71;
1.2)°
0.57 0.116
Table 3: Modifications of biochemical and redox variables, measured before and after each respective replacement diet. Data are reported as mean
and standard deviation. MDA=Malondialdehyde; ROS=Reactive Oxygen Species; TAC=Total Antioxidant Capacity. *p<0.05 for paired T-test (pre
vs post). °p<0.05 for independent T-test (for changes between the buckwheat and control groups). †General linear model adjusted for age, gender,
BMI, smoking habits, hypertension and dyslipidemia.
The changes in total and LDL cholesterol, and insulin were
significantly different (p<0.05) between the two study arms. A similar
result was shown for ROS production by lymphocytes. This was
ascribed to improved values within the buckwheat group, with no
significant changes in the control group (except for ROS production).
Mean percentage change in lipid, gluco-metabolic and various
oxidative stress-related parameters are shown in Figure 1.
The replacement diet with buckwheat products was found to result
in a significant reduction (p<0.05) in plasma levels of total cholesterol
(mean reduction: -9.4 mg/dL; -4.7%), LDL cholesterol (-10.4 mg/dL;
-8.4%), as well as triglycerides (-17 mg/dL; -15%). Glucose levels and
the HOMA-Index decreased significantly by 5.7% and 22.7%
respectively (-5.1 mg/dL and -0.5). A reduction in the insulin levels
was also observed (-1.7 U/L; -17%), although this was not significant.
With regard to the oxidative stress profile, a significant amelioration in
TBARs levels (-14.7 pg/mL; -29.5%) and an increase by 9.7% in
antioxidant activity were reported. In contrast, no differences in any of
these parameters were observed after the intervention period with
control products. ROS production increased significantly in the control
group, compared to the buckwheat intervention group (Table 3).
Serum electrolyte content was not significantly changed after
consumption of either the buckwheat-enriched products or the control
products (results not shown).
With regard to the inflammatory parameters, monocyte chemotactic
protein-1 (MCP-1) and macrophage inflammatory protein-1beta
(MIP-1beta) were significantly reduced after consumption of both
buckwheat-enriched products and the control (Table 4). There were no
further improvements in the inflammatory profile of the buckwheat-
enriched products over that of the control (Table 4).
Discussion
The aim of the present study was to investigate whether a two-
month replacement diet using common buckwheat (Fagopyrum
esculentum)-enriched wheat food products on an Italian population
(at risk for cardiovascular problems) could provide additive protective
effects in reducing cardiovascular risk factors, including blood glucose,
insulin, lipids, oxidative damage and pro-inflammatory markers.
Hence, the objective was to investigate potential hypocholesterolemic,
hypoglycemic, anti-oxidant and anti-inflammatory effects, considered
important in reducing CVD risk.
Most studies conducted to date, have investigated the effect of
various buckwheat extracts or individual molecular components on
cell lines and animal models, with relatively few studies being
performed on humans. [5] The present study provided a valuable
contribution in this context, particularly with regard to investigating
the potential anti-inflammatory effect. Of relevance, it was possible to
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examine the above-mentioned parameters, after the consumption of
the buckwheat-enriched wheat as the staple carbohydrate source in the
diet. The effects were then compared with those obtained after the
consumption of modern wheat alone on the same population of Italian
individuals, traditionally accustomed to wheat as a staple carbohydrate
source. The results showed a positively impact on CVD risk by down-
regulating several key parameters associated with the disease.
Consumption of the buckwheat-enriched wheat products displayed
hypocholesterolemic effects, including the significant reduction of total
cholesterol and LDL-cholesterol, as well as a decrease in the
triglyceride content. This effect was not observed after the
consumption of the modern wheat alone. Given that LDL is the
predominant cholesterol risk factor for CVD [9], successful dietary/
lifestyle treatments aimed at reducing this parameter are warranting of
attention in primary prevention. Various mechanisms, including
decreased lipid absorption and effects on lipid metabolic enzymes have
been proposed but the individual buckwheat compounds responsible
for the underlying effects are unknown [5].
Buckwheat is also considered a low glycemic index (GI) food, and it
has been shown that low-GI diets promote significantly improved lipid
profiles in medium- and longer-term interventions, particularly with
regard to reducing both total cholesterol and LDL-cholesterol levels
[10-12]. Of the many potential mechanisms in regulating glucose
levels, buckwheat is renowned for containing various bioactive
substances (such as d-chiro-inositol, and various polyphenols), which
have been shown to be exercise a positive impact on either insulin or
glucose metabolism in animal models [4]. The present study verified
positive cholesterol-lowering and hypoglycemic effects after only two
months of consumption. The hypoglycemic effect was evident from the
significant reduction in the HOMA-index, reflecting the respective
decreases in glucose and insulin. Maintenance of glucose homeostasis,
by targeting lifestyle interventions, is an essential primary prevention
strategy towards preventing the development of type 2 diabetes
mellitus [13] and in reducing CVD risk.
Figure 1: Mean percentage of change in serum levels of lipid
parameters, glucometabolic parameters, thiobarbituric acid reactive
substances (TBARS) and oxygen radical absorbance capacity
(ORAC) with buckwheat products versus control products after 8
weeks of dietary intervention (* p<0.05).
In addition, the results from the present dietary trial showed that
consumption of buckwheat-enriched products were able to improve
circulatory TAC, thereby corroborating previous work showing the
efficacy of short-term interventions on this parameter using 30%
buckwheat-enriched bread [14]. An improved TAC following
consumption of buckwheat was suggested to be attributable to
bioactive peptide fragments capable of stabilizing ROS, and the
elevated polyphenol content [4]. A significantly higher polyphenol
content and anti-radical activity was evident in the buckwheat-
enriched semolina and flour, compared to the modern wheat control.
Therefore, it is highly probable that the improved TAC and reduced
lipid peroxidation damage were associated with the well-documented
antioxidant benefits attributed to buckwheat [5].
Monocyte chemotactic protein-1 (MCP-1) and macrophage
inflammatory protein-1beta (MIP-1beta) were significantly reduced
after consumption of both buckwheat-enriched products and the
control. Previous work published by this group [7], similarly showed
improvements in MCP-1 and MIP-1beta in a healthy population, after
two-month period, following the consumption of both khorasan wheat
and the same modern control products. However, consumption of
buckwheat-enriched products did not result in any additional
improvements to the inflammatory profile. The present study
represents one of the very few conducted to investigate potential anti-
inflammatory benefits of buckwheat, and is novel being an in vivo
study on humans. Polyphenols have been reported to exert anti-
inflammatory activity via the modulation of the oxygen-stress-sensitive
nuclear factor (NF-κB), which mediates the expression of important
pro-inflammatory cytokines such as TNF-alpha, Il-6 and VEGF [2].
Notwithstanding, the significantly higher polyphenol content and anti-
radical activity of the buckwheat-enriched semolina and flour (in
comparison to the modern wheat) it would appear that within the
framework of the present study, the beneficial effects may be limited to
traditional anti-oxidant activity. However, more studies on humans are
warranting.
Given that the study population was relatively small in size, studies
on a larger population are needed to verify the present results.
However, there were overall significant changes in various parameters,
which could be independently attributed to the replacement diet. Body
weight did not change significantly after the trial, thereby showing that
patients adhered to their normal habits relating to carbohydrate
consumption. Hence, the beneficial effects were not associated with
weight loss, but rather with the ingestion of buckwheat-enriched wheat
products.
In conclusion, a replacement diet with buckwheat-enriched
products impacted positively by down-regulating several key
parameters associated with CVD risk, including total cholesterol, LDL-
cholesterol, blood glucose, insulin, and the HOMA index. No
improvements in the inflammatory profile were observed in the
present studies that were specifically related to the consumption of
buckwheat products. Additional research is necessary to further
investigate the possible beneficial effect of this pseudo-cereal.
Variables
Buckwheat p † Control
p†
p for
change†
pre post change pre post change
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Interleukin-1ra,
pg/mL 25.5 ± 39.1 17.3 ± 16.3
-8.2 (-22.1;
5.7) 0.2 39.5 ± 100.9 25.4 ± 55.8 *
-14.1 (-38.9;
10.6) 0.22 0.3
Interleukin-4,
pg/mL 0.3 ± 0.3 0.3 ± 0.3
-0.08 (-0.2,
0.02) 0.09 0.4 ± 0.3 0.3 ± 0.3
-0.04 (-0.1;
0.03) 0.23 0.465
Interleukin-6,
pg/mL 3.2 ± 1.7 3.2 ± 1.7
-0.05 (-0.9;
0.8) 0.89 3.7 ± 2.2 2.8 ± 1.6 *
-0.9 (-1.3;
-0.5) 0 0.033
Interleukin-8,
pg/mL 28.3 ± 33.3 18.6 ± 27.1 *
-9.7 (-20.7;
1.3) 0.07 23.8 ± 29.9 29 ± 60.2
5.2 (-13.8;
24.2) 0.55 0.142
Interleukin-10,
pg/mL 5.3 ± 2.6 5 ± 3.5
-0.3 (-1.7;
1.2) 0.67 7.7 ± 9.1 4.5 ± 3.2 *
-3.1 (-6.7;
0.5) 0.07 0.172
Interleukin-12,
pg/mL 10.7 ± 4.6 9 ± 4.1
-1.7 (-4.2;
0.8) 0.15 12.7 ± 6.8 9.4 ± 4 *
-3.3 (-5.1;
-1.5) 0 0.329
Interleukin-17,
pg/mL 3.1 ± 2.1 2.8 ± 2.3
-0.4 (-1.5;
0.7) 0.44 3.5  ± 1.7 2.7 ± 1.6
-0.8 (-1.8;
0.1) 0.09 0.498
Ip-10, pg/mL 871.8 ± 677.7 785.6 ± 489.4
-86.2
(-276.5;
104)
0.32 867.4 ± 529.5 888.4 ± 504.2 21.1 (121.9;164.1) 0.74 0.369
MCP-1, pg/mL 57.1 ± 38.4 47.2 ± 29.9 * -9.9 (-18.1;-1.6) 0.02 51.7 ± 30.5 42.5 ± 26.2
-9.2 (-14.2;
-4.3) 0 0.857
MIP-1beta, pg/mL 172.8 ± 93.4 142.2 ± 60.6 * -30.6 (-53.7;-7.4) 0.01 167.5 ± 64.7 143.9 ± 64.4
-23.6 (-40;
-7.2) 0.02 0.513
TNF-alpha, pg/mL 6.1 ± 3.4 6.7 ± 7.1 0.6 (-3.3;4.5) 0.74 9.1 ± 7.2 6.6 ± 4.2 -2.5 (-6; 0.9) 0.12 0.226
VEGF, pg/mL 83.3 ± 36.1 76.  ± 36.1 -6.4 (-18.2;5.3) 0.24 84 ± 32.8 73.4 ± 37.9 *
-10.6 (-23.4;
2.3) 0.09 0.502
Table 4: Modifications in the inflammatory profile. Ip-10=Interferon Gamma-Induced Protein 10; MCP-1=Monocyte Chemotactic Protein-1;
MIP-1 beta=Macrophage Inflammatory Protein-1 beta; TNF-alpha=Tumour Necrosis Factor-alpha; VEGF=Vascular Endothelial Growth Factor
Data are reported as mean and standard deviation. *p<0.05 for paired T-test (pre vs post). †General linear model adjusted for age, gender, BMI,
smoking habits, hypertension and dyslipidemia.
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